ArticleAnnals of the Royal College of Surgeons of England2022
Hashimoto's thyroiditis on outcomes in papillary thyroid cancer revisited: experience from South East Asia.
Article in Annals of the Royal College of Surgeons of England, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- The dual oncogenic and protective roles of hashimoto's thyroiditis in papillary thyroid carcinoma: a cohort-based meta-analysis.World journal of surgical oncology · 2026Pooled it
- Radioactive iodine therapy for thyroid cancer coexisting with Hashimoto's thyroiditis: a systematic review and meta-analysis.The British journal of radiology · 2024Pooled it
- Association between autoimmune thyroiditis and clinicopathological features of papillary thyroid carcinoma: a prospective study.Archives of endocrinology and metabolism · 2026Article
- Impact of Hashimoto Thyroiditis on Long-Term Outcomes in Differentiated Thyroid Carcinoma.Cancers · 2026Article
- Dual Role of AITD in TgAb-Positive PTC: Delayed Antibody Clearance with Enhanced RAIT Response.Cancer management and research · 2026Article
- Is conformal thyroidectomy feasible? A 5-10-year follow-up study of residual thyroid in 2512 cases after thyroidectomy.World journal of surgical oncology · 2025Article
- Papillary thyroid carcinoma with Hashimoto's thyroiditis: impact and correlation.Frontiers in endocrinology · 2025Review
- Surgical management of papillary thyroid carcinoma coexisting with Hashimoto's disease: a single-center retrospective cohort study.Frontiers in endocrinology · 2024Observational
- Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with Hashimoto's thyroiditis.Heliyon · 2023Article
- Prediction of papillary thyroid metastases to the central compartment: proposal of a model taking into consideration other thyroid conditions.Frontiers in endocrinology · 2023Article
- Identification of Long Noncoding RNAs Associated With the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated With Hashimoto's Thyroiditis.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe association between Hashimoto Thyroiditis (HT) and papillary thyroid cancer (PTC) remains uncertain. HT, the most common inflammatory condition of the thyroid, is postulated to increase the risk of PTC and yet confer cancer-retarding effects. In this study, we aim to evaluate the prevalence of HT in patients surgically treated for PTC and evaluate the long-term prognostic implications.
methodsThis is a retrospective study of 521 patients with PTC who underwent hemi- or total thyroidectomy between January 2000 and December 2018 at a tertiary referral centre. Patients were categorised into two group: group A (
resultsA total of 521 patients with a mean age of 46.7 years were evaluated. HT was detected in 22.8% of patients with PTC. On multivariate analysis, presence of HT was associated with a lower incidence of extrathyroidal extension (hazard ratio: 0.59, 95%confidence interval 0.37-0.95). Also, patients with HT tend to have fewer cycles of radioactive iodine and correspondingly have excellent response to treatment. However, no differences in recurrence rates and overall survival were detected.
conclusionsOne-fifth of patients with PTC have coexisting HT. These patients tend to have less-aggressive tumour features such as extrathyroidal extension. However, the effect of HT on recurrence and overall survival appears to be inconsequential clinically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.